JP2020537654A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020537654A5 JP2020537654A5 JP2020521453A JP2020521453A JP2020537654A5 JP 2020537654 A5 JP2020537654 A5 JP 2020537654A5 JP 2020521453 A JP2020521453 A JP 2020521453A JP 2020521453 A JP2020521453 A JP 2020521453A JP 2020537654 A5 JP2020537654 A5 JP 2020537654A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- peptide
- acceptable salt
- oligonucleotide conjugate
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 *CC1OC(*)CN(CN=C)C1 Chemical compound *CC1OC(*)CN(CN=C)C1 0.000 description 7
- WDEMIXBRPVTUPL-UHFFFAOYSA-N CC(C)N(CC1)CCN1C(C(C)(C)OCCC(C)(C)O)=O Chemical compound CC(C)N(CC1)CCN1C(C(C)(C)OCCC(C)(C)O)=O WDEMIXBRPVTUPL-UHFFFAOYSA-N 0.000 description 2
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023071470A JP7702444B2 (ja) | 2017-10-17 | 2023-04-25 | アンチセンス送達のための細胞透過性ペプチド |
| JP2025032837A JP2025087783A (ja) | 2017-10-17 | 2025-03-03 | アンチセンス送達のための細胞透過性ペプチド |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762573379P | 2017-10-17 | 2017-10-17 | |
| US62/573,379 | 2017-10-17 | ||
| PCT/US2018/056205 WO2019079386A1 (en) | 2017-10-17 | 2018-10-17 | CELL PENETRATION PEPTIDES FOR ANTISENSE ADMINISTRATION |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023071470A Division JP7702444B2 (ja) | 2017-10-17 | 2023-04-25 | アンチセンス送達のための細胞透過性ペプチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020537654A JP2020537654A (ja) | 2020-12-24 |
| JP2020537654A5 true JP2020537654A5 (enExample) | 2021-11-11 |
| JP7320500B2 JP7320500B2 (ja) | 2023-08-03 |
Family
ID=66174189
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020521453A Active JP7320500B2 (ja) | 2017-10-17 | 2018-10-17 | アンチセンス送達のための細胞透過性ペプチド |
| JP2023071470A Active JP7702444B2 (ja) | 2017-10-17 | 2023-04-25 | アンチセンス送達のための細胞透過性ペプチド |
| JP2025032837A Pending JP2025087783A (ja) | 2017-10-17 | 2025-03-03 | アンチセンス送達のための細胞透過性ペプチド |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023071470A Active JP7702444B2 (ja) | 2017-10-17 | 2023-04-25 | アンチセンス送達のための細胞透過性ペプチド |
| JP2025032837A Pending JP2025087783A (ja) | 2017-10-17 | 2025-03-03 | アンチセンス送達のための細胞透過性ペプチド |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US12138312B2 (enExample) |
| EP (1) | EP3697422A4 (enExample) |
| JP (3) | JP7320500B2 (enExample) |
| MA (1) | MA50834A (enExample) |
| TW (2) | TW202423453A (enExample) |
| WO (1) | WO2019079386A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019178479A1 (en) * | 2018-03-16 | 2019-09-19 | Sarepta Therapeutics, Inc. | Chimeric peptides for antisense delivery |
| WO2021150867A1 (en) * | 2020-01-24 | 2021-07-29 | Sarepta Therapeutics, Inc. | Designing antisense oligonucleotide delivery peptides by interpretable machine learning |
| CN116670293A (zh) * | 2020-12-16 | 2023-08-29 | 先锋国际良种公司 | 昆虫细胞内细胞穿透肽介导的rna转导 |
| US20250011777A1 (en) * | 2021-09-03 | 2025-01-09 | Sarepta Therapeutics, Inc. | Delivery of anitsense oligomers by mirror image peptides |
| CN114380886B (zh) * | 2022-01-26 | 2022-10-21 | 深圳深创生物药业有限公司 | 一种肿瘤靶向多肽、多肽偶联药物及其应用 |
| EP4230196A1 (en) | 2022-02-21 | 2023-08-23 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of dystrophinopathies |
| JP2025537104A (ja) * | 2022-11-02 | 2025-11-14 | サレプタ セラピューティクス， インコーポレイテッド | アンチセンスオリゴマーコンジュゲートの製剤化 |
| WO2025030099A1 (en) * | 2023-08-02 | 2025-02-06 | Sarepta Therapeutics, Inc. | Non-canonical cell-penetrating peptides for antisense oligomer delivery |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2657400T3 (es) | 2006-05-10 | 2018-03-05 | Sarepta Therapeutics, Inc. | Análogos de oligonucleótidos que tienen enlaces intersubunitarios catiónicos |
| AU2008271050B2 (en) * | 2007-06-29 | 2014-11-06 | Sarepta Therapeutics, Inc. | Tissue specific peptide conjugates and methods |
| US20100016215A1 (en) | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| WO2012150960A1 (en) * | 2011-05-05 | 2012-11-08 | Avi Biopharma, Inc. | Peptide oligonucleotide conjugates |
| US9161948B2 (en) * | 2011-05-05 | 2015-10-20 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
| MX363734B (es) * | 2011-10-27 | 2019-03-29 | Massachusetts Inst Technology | Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco. |
| MX369519B (es) * | 2012-09-25 | 2019-11-11 | Genzyme Corp | Oligonucleotidos antisentido morfolino unidos a peptido para el tratamiento de distrofia miotonica. |
| WO2014124952A1 (en) | 2013-02-12 | 2014-08-21 | Syddansk Universitet | "clickable" alkyne-lna oligonucleotides |
| WO2017066789A1 (en) * | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Mrna cap analogs with modified sugar |
| WO2019178479A1 (en) * | 2018-03-16 | 2019-09-19 | Sarepta Therapeutics, Inc. | Chimeric peptides for antisense delivery |
-
2018
- 2018-10-17 TW TW112133920A patent/TW202423453A/zh unknown
- 2018-10-17 TW TW107136614A patent/TWI837102B/zh active
- 2018-10-17 EP EP18868379.1A patent/EP3697422A4/en active Pending
- 2018-10-17 MA MA050834A patent/MA50834A/fr unknown
- 2018-10-17 WO PCT/US2018/056205 patent/WO2019079386A1/en not_active Ceased
- 2018-10-17 US US16/756,616 patent/US12138312B2/en active Active
- 2018-10-17 JP JP2020521453A patent/JP7320500B2/ja active Active
-
2023
- 2023-04-25 JP JP2023071470A patent/JP7702444B2/ja active Active
-
2024
- 2024-08-09 US US18/799,673 patent/US20250135015A1/en active Pending
-
2025
- 2025-03-03 JP JP2025032837A patent/JP2025087783A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020537654A5 (enExample) | ||
| JP5271913B2 (ja) | 化合物 | |
| JP2020503009A5 (enExample) | ||
| JP2020022483A5 (enExample) | ||
| RU2005118421A (ru) | 2'-разветвленные нуклеозиды и мутация flaviviridae | |
| CN1414854A (zh) | 膦酸酯化合物 | |
| US20110245458A1 (en) | Peptide nucleic acid monomers and oligomers | |
| CA3007065C (en) | Salts of conjugates for cancer therapy | |
| CN101415719A (zh) | 生产2’-脱氧-β-L-核苷的方法 | |
| JP2021182946A5 (enExample) | ||
| CN107074911B (zh) | 肽核酸单体和低聚体 | |
| JP2020525502A5 (enExample) | ||
| SA98190103B1 (ar) | مركبات 5‘-ديوكسي-سيتيدين 5 deoxy cytidine -وإستخدامها كعوامل مضادة لورم anti tumor | |
| JP2018525015A5 (enExample) | ||
| US10239910B2 (en) | Process for the preparation of sofosbuvir | |
| JP2020537652A5 (enExample) | ||
| JPWO2023127752A5 (enExample) | ||
| JP2018518167A5 (enExample) | ||
| JPWO2020028254A5 (enExample) | ||
| JPWO2023178230A5 (enExample) | ||
| JPWO2019178479A5 (enExample) | ||
| AU2012216500B2 (en) | Nucleoside aryl phosphoramidates and their use as anti-viral agents for the treatment of hepatitis C virus | |
| EP3962918A1 (en) | Novel process for preparing rhenium chelated mag3 oligonucleotides | |
| NZ747165A (en) | Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene | |
| JPWO2022140535A5 (enExample) |